Our History
1989
Inception as contract manufacturer for Bulk Drug
1991
API and Bulk Drug Manufacturing – Commenced production at Bidar, Karnataka.
Manufacturing of API’s and Bulk Drugs such as Ibuprofen, Chlorzoxazone, Nalidixic Acid.
1997
Exploration into Specialty Chemicals- VIV-20 Patent grant by Indian Patents Office
Foray into specialty chemicals through development and process innovation of Anti-Bacterial Viv-20 (Triclosan)
2000
Breakthrough in Specialty Chemicals
Established R&D center Approved by Unilever for the supply of Viv-20 and Vivcal-G to Unilever’s Asian locations
2005
Expansion of Product Portfolio & Clientele
Listed on BSE & NSE
Development of new active ingredients
Introduction of Small Volume Parentals facility and Specialty Chemicals facility
Added new customers such as L’Oreal, P&G
Inorganic Growth Healthcare
Acquired Uquifa, Octtantis Nobel, Klar Sehen, Finoso and Actavis SOD facility to increase presence in API’s & formulations
Active Ingredients: Acquired James Robinson to increase global presence and increase product portfolio
2011
Embarked upon building an integrated Healthcare company vis-à-vis pure play Spechem player
Acquired Uquifa which marked Vivimed’s entry into the API domain; added new customers, diversified product portfolio and 3 USFDA approved manufacturing facilities.
Acquired Klar Sehen and Octantis Nobel to establish footprint in the domestic FDF market as branded manufacturer
2012
Harnessing the future
Focused on strengthening the API business with backward integration and procurement synergies
2013
Investment for future pipeline
Commissioning of Bidar block for Pharma Intermediates
Upgradation of Jeedimetla facility to PICS standards
Established API R&D with 65 scientists and formulations R&D with 45 scientists
Health Canada approval for FR&D centre
2014
Focused on integration and simulation
Acquisition of APMPL, a US FDA approved FDF facility has opened doors in the regulated markets for generics
Recent PIC/S GMP approval; access to the regulated CIS market for formulations
All building blocks in place to take healthcare segment to the next level of growth
2015
Personal Care Divesture to Clariant